Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
Tevogen Bio (NASDAQ:TVGN) has announced the completion and opening of its expanded corporate headquarters in Warren, New Jersey. The notable aspect of this expansion is that the build-out and first-year operating costs were personally funded by CEO Ryan Saadi, M.D., M.P.H., incurring no expenses for the company or shareholders.
The new facility has more than doubled the company's previous footprint and consolidates multiple teams including research, regulatory affairs, and the growing Tevogen.AI initiative under one roof. The expansion was completed ahead of schedule, and the company plans to host a formal ribbon-cutting ceremony with local officials, employees, and community partners.
Tevogen Bio (NASDAQ:TVGN) ha annunciato il completamento e l'apertura della sua sede aziendale ampliata a Warren, New Jersey. L'aspetto rilevante di questa espansione è che i costi di costruzione e di funzionamento del primo anno sono stati finanziati personalmente dal CEO Ryan Saadi, M.D., M.P.H., senza alcuna spesa per l'azienda o per gli azionisti.
La nuova struttura ha più che raddoppiato lo spazio precedentemente occupato dall'azienda e ha riunito sotto lo stesso tetto diversi team, tra cui quelli di ricerca, affari regolatori e l'iniziativa in crescita Tevogen.AI. L'espansione è stata completata in anticipo rispetto ai tempi previsti e l'azienda prevede di organizzare una cerimonia ufficiale di inaugurazione con funzionari locali, dipendenti e partner della comunità.
Tevogen Bio (NASDAQ:TVGN) ha anunciado la finalización y apertura de su sede corporativa ampliada en Warren, Nueva Jersey. Lo notable de esta expansión es que los costos de construcción y operación del primer año fueron financiados personalmente por el CEO Ryan Saadi, M.D., M.P.H., sin generar gastos para la empresa ni para los accionistas.
La nueva instalación ha más que duplicado el espacio previo de la compañía y consolida varios equipos, incluyendo investigación, asuntos regulatorios y la creciente iniciativa Tevogen.AI, bajo un mismo techo. La expansión se completó antes de lo previsto y la empresa planea realizar una ceremonia formal de inauguración con funcionarios locales, empleados y socios comunitarios.
Tevogen Bio (NASDAQ:TVGN)가 뉴저지 주 워렌에 위치한 확장된 본사 건물의 완공 및 개장을 발표했습니다. 이번 확장의 주목할 점은 건설 및 첫 해 운영 비용이 CEO Ryan Saadi, M.D., M.P.H.가 개인 자금으로 부담하여 회사나 주주에게 비용이 전혀 발생하지 않았다는 점입니다.
새 시설은 회사의 이전 공간을 두 배 이상 확장했으며, 연구팀, 규제 업무팀, 그리고 성장 중인 Tevogen.AI 이니셔티브 등 여러 팀을 한 곳에 통합했습니다. 확장은 예정보다 일찍 완료되었으며, 회사는 지역 관계자, 직원 및 지역사회 파트너들과 함께 공식 개장식을 개최할 계획입니다.
Tevogen Bio (NASDAQ:TVGN) a annoncé l’achèvement et l’ouverture de son siège social agrandi à Warren, dans le New Jersey. Ce qui est remarquable dans cette expansion, c’est que les coûts de construction et d’exploitation de la première année ont été personnellement financés par le PDG Ryan Saadi, M.D., M.P.H., sans engendrer de dépenses pour l’entreprise ni pour les actionnaires.
La nouvelle installation a plus que doublé la surface précédemment occupée par l’entreprise et regroupe sous un même toit plusieurs équipes, notamment la recherche, les affaires réglementaires et l’initiative en pleine croissance Tevogen.AI. L’agrandissement a été achevé avant la date prévue, et l’entreprise prévoit d’organiser une cérémonie officielle d’inauguration avec les autorités locales, les employés et les partenaires communautaires.
Tevogen Bio (NASDAQ:TVGN) hat den Abschluss und die Eröffnung seines erweiterten Firmensitzes in Warren, New Jersey, bekannt gegeben. Bemerkenswert an dieser Erweiterung ist, dass die Bau- und Betriebskosten des ersten Jahres persönlich vom CEO Ryan Saadi, M.D., M.P.H., finanziert wurden, wodurch dem Unternehmen und den Aktionären keine Kosten entstanden.
Die neue Einrichtung hat die bisherige Fläche des Unternehmens mehr als verdoppelt und vereint mehrere Teams, darunter Forschung, Regulierungsangelegenheiten und die wachsende Tevogen.AI-Initiative, unter einem Dach. Die Erweiterung wurde vor dem Zeitplan abgeschlossen, und das Unternehmen plant eine offizielle Eröffnungsfeier mit lokalen Vertretern, Mitarbeitern und Partnern aus der Gemeinschaft.
- CEO personally funded headquarters expansion and first-year operations, preserving company capital
- More than doubled headquarters footprint to accommodate growth
- Centralization of research, regulatory, and AI teams expected to improve operational efficiency
- Completion of facility ahead of schedule indicates strong project execution
- Company may need to raise additional capital for future operations as stated in forward-looking statements
- Limited operating history poses execution risks
- Significant dependence on future capital raising which may not be available on favorable terms
- CEO's personal contribution fully funds build-out and first-year operations
- Doubled HQ footprint centralizes cross-functional teams, including research, regulatory affairs, and the expanding Tevogen.AI initiative
WARREN, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the completion and official opening of its fully functional, newly expanded corporate headquarters in Warren, New Jersey. The build-out and first-year operating costs were personally gifted by Founder and Chief Executive Officer Ryan Saadi, M.D., M.P.H., resulting in no expense to the Company or its shareholders.
Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogen’s previous footprint and brings research, regulatory, and the expanding Tevogen.AI teams together under one roof.
A formal ribbon-cutting ceremony is being planned at the new site and will host local officials, employees, and community partners.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1c3c5ad5-f4c3-4a52-8b63-28327e9a3198
FAQ
What is the significance of Tevogen's new headquarters announcement?
How is Tevogen (TVGN) funding its new headquarters expansion?
What teams will be housed in Tevogen's new Warren, NJ headquarters?
What are the main risks mentioned in Tevogen's headquarters announcement?
When will Tevogen's new headquarters officially open?
